Development of this pharmaceutical is carried out according to EU-requirements in country without patent protection or with Bolar-provisions. There will be no sales in those countries where this offer would constitute an infringement of third parties intellectual proprietary rights.

Repaglinide belongs to the meglitinide class of blood glucose-lowering drugs.

Repaglinide lowers blood glucose by stimulating the release of insulin from the pancreas. It achieves this by closing ATP-dependent potassium channels in the membrane of the beta cells. This depolarizes the beta cells, opening the cells' calcium channels, and the resulting calcium influx induces insulin secretion.

More details at: http://www.rxlist.com/prandin-drug.htm.

• Insulin antidiabetics (09/10/2008)
• Non-insulin antidiabetics (10/06/2008)
• Orphan Diseases in CNS - Part II (16/05/2008)

• Ropinirole HCl (17/09/2009)
• Olanzapine- mouth dissolving tablets (17/09/2009)
• Oxcarbazepine (17/09/2009)
• Losartan potassium-hydrochlorothiazide (17/09/2009)
• Levofloxacin hemihydrate (17/09/2009)
• Pantoprazole tablets (17/09/2009)
• Buprenorfine Sublingual Tablets (15/04/2009)
• EU-CTD Dossiers of Generic Drugs with Product Supply (02/07/2008)
• Peg GCSF (26/05/2008)